Search

CRISPR/Cpf1 Gene Editing Systems Using Recombinant AsCpf1 and LbCpf1 crRNA

The USPTO published patent application US20260098249A1 for Integrated DNA Technologies covering recombinant AsCpf1 and LbCpf1 nucleic acids and polypeptides for CRISPR/Cpf1 endonuclease gene editing systems in mammalian cell lines. The application includes ribonucleoprotein complexes using length-truncated, chemically-modified, or dual-modified AsCpf1 crRNAs and methods for performing gene editing using these systems.

siRNA Molecules Targeting ATXN3 Gene for Spinocerebellar Ataxia Treatment

The USPTO published patent application US20260098265A1 disclosing single- or double-stranded siRNA molecules targeting the ataxin-3 (ATXN3) gene for treatment of spinocerebellar ataxias, including spinocerebellar ataxia type 3. The application includes branched siRNA designs (di-branched, tri-branched, tetra-branched) with nucleoside modifications, 5' phosphorus stabilizing moieties, and methods for CNS delivery. The application was filed on September 28, 2023.

Maribavir Antiviral Drug Patent, Five Inventors, Filed 2025

Maribavir Antiviral Drug Patent, Five Inventors, Filed 2025

Trisubstituted Benzotriazole Derivatives as Dihydroorotate Oxygenase Inhibitors for Cancer Treatment

USPTO published patent application US20260097019A1 disclosing trisubstituted benzotriazole derivatives as dihydroorotate oxygenase inhibitors for treating cancer and inhibiting tumor growth and metastasis. Inventors: Kavitha Nellore and Subramanya Hosahalli. Application filed April 30, 2025.

Stable Amlodipine Oral Liquid Formulations for Hypertension and CAD Treatment

USPTO published patent application US20260097025A1 for stable amlodipine oral liquid formulations filed by inventors Scott Brauer and Gerold L. Mosher. The application covers formulations containing amlodipine for treating hypertension and Coronary Artery Disease (CAD), with CPC classifications in A61K therapeutic preparations. The application was filed on June 17, 2025, under application number 19240194.

Therapeutic Use of Aromatase Inhibitors and PARP Inhibitors for Treatment of Malignancies

USPTO published patent application US20260097020A1 covering methods for treating gliomas including glioblastoma using aromatase inhibitors such as letrozole, optionally combined with PARP inhibitors (olaparib, pamiparib, veliparib, or niraparib). The application was filed September 30, 2025 under application number 19345169. Inventors include Pankaj B. Desai, Aniruddha S. Karve, Bhavesh B. Gabani, Sidharth N. Gadgil, and Gary A. Gudelsky.

Unit Oral Dose Compositions of Ibuprofen and Famotidine for Acute Pain and Heartburn Reduction

The USPTO published patent application US20260097023A1 for unit oral dose compositions combining ibuprofen (50-400 mg) and famotidine (3-20 mg) designed to treat acute pain while reducing the severity or risk of heartburn and upset stomach. The formulation specifies that famotidine must dissolve faster than ibuprofen within 45 minutes of administration. The application was filed on December 2, 2025, by inventor Bernard Schachtel.

Buprenorphine Depot Formulation Controlled-Release Matrix

USPTO published patent application US20260097031A1 for a depot precursor formulation comprising a controlled-release matrix with an oxygen-containing organic solvent and at least 12% by weight buprenorphine or salts thereof. Inventors include Fredrik Tiberg, Ian Harwigsson, and Markus Johnsson. The application covers methods for pain management and opioid maintenance treatment.

Ether Lipids Hyperactivate Dendritic Cells - Corner Therapeutics

The USPTO published patent application US20260097111A1 by Corner Therapeutics, Inc. on April 9, 2026, covering ether lipid (ETL) and ether phospholipid (ETPL) compounds for hyperactivating mammalian dendritic cells, including compositions combined with pathogen recognition receptor agonists, antigens, and dendritic cells. The application was originally filed on October 18, 2023.

Liposomal Compositions With Anti-Cancer Agents, Tumor-Targeting Lipopeptides

The USPTO published patent application US20260096988A1 on April 9, 2026, filed by inventors Debabrata Mukhopadhyay, Vijay S. Madamsetty, and Krishnendu Pal. The application covers liposomal compositions containing anti-cancer agents and tumor-targeting lipopeptides, as well as nanodiamond complexes and particles as carriers for anti-cancer agents. This publication provides public notice of the intellectual property claims related to advanced drug delivery compositions for cancer treatment. The pharmaceutical and biotechnology industries should monitor this application for potential impacts on cancer therapeutics development.